Oncolys BioPharma Full Year 2024 Earnings: JP¥77.17 loss per share (vs JP¥109 loss in FY 2023)

Oncolys BioPharma (TSE:4588) Full Year 2024 Results

Key Financial Results

• Net loss: JP¥1.68b (loss narrowed by 13% from FY 2023).
• JP¥77.17 loss per share (improved from JP¥109 loss in FY 2023).

4588 Products In Clinical Trials

• Phase I: 3.
• Phase II: 6.

All figures shown in the chart above are for the trailing 12 month (TTM) period

In the last 12 months, the only revenue segment was Drug Discovery Business contributing JP¥31.4m. The largest operating expense was General & Administrative costs, amounting to JP¥1.72b (100% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of JP¥2.83m. Explore how 4588's revenue and expenses shape its earnings.

Oncolys BioPharma shares are up 15% from a week ago.

Risk Analysis

You should learn about the 4 warning signs we've spotted with Oncolys BioPharma (including 3 which are potentially serious).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.